These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 3345615)

  • 1. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (delapril) in patients with deteriorated kidney function and in normal control subjects.
    Onoyama K; Nanishi F; Okuda S; Oh Y; Fujishima M; Tateno M; Omae T
    Clin Pharmacol Ther; 1988 Mar; 43(3):242-9. PubMed ID: 3345615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers.
    Hutt V; Pabst G; Dilger C; Poli G; Acerbi D
    Eur J Drug Metab Pharmacokinet; 1994; 19(1):59-69. PubMed ID: 7957454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and acute effect on the renin-angiotensin system of delapril in patients with chronic renal failure.
    Shionoiri H; Yasuda G; Abe Y; Yoshimura H; Kaneko Y; Shindo Y
    Clin Nephrol; 1987 Feb; 27(2):65-70. PubMed ID: 3030595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depressor effects and pharmacokinetics of single and consecutive doses of delapril in hypertensive patients with normal or impaired renal function.
    Minamisawa K; Shionoiri H; Sugimoto K; Ueda S; Ashino K; Ebina T; Gotoh E; Ishii M
    Cardiovasc Drugs Ther; 1990 Oct; 4(5):1417-23. PubMed ID: 2177631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and tolerability of a new manidipine and delapril fixed oral combination in young and elderly subjects.
    Stockis A; De Bruyn S; Gengler C; Goethals F; Lens S; Poli G; Acerbi D
    Arzneimittelforschung; 2003; 53(8):554-61. PubMed ID: 13677245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single oral dose pharmacokinetic interaction study of manidipine and delapril in healthy volunteers.
    Stockis A; Gengler C; Goethals F; Jeanbaptiste B; Lens S; Poli G; Acerbi D
    Arzneimittelforschung; 2003; 53(9):627-34. PubMed ID: 14558436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensin-converting enzyme inhibitor.
    Razzetti R; Acerbi D
    Am J Cardiol; 1995 Jun; 75(18):7F-12F. PubMed ID: 7778536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The long-term effects of a new converting enzyme inhibitor, delapril hydrochloride, on renal function, renin-angiotensin-aldosterone system and kallikrein-kinin prostaglandin system in hypertensive patients].
    Nishiyama K; Igari T; Nanba S; Ishii M
    Nihon Jinzo Gakkai Shi; 1990 Jul; 32(7):801-7. PubMed ID: 2273596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.
    Hoyer J; Schulte KL; Lenz T
    Clin Pharmacokinet; 1993 Mar; 24(3):230-54. PubMed ID: 8462229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and depressor effect of delapril in patients with essential hypertension.
    Shionoiri H; Yasuda G; Ikeda A; Ohta T; Miyajima E; Kaneko Y
    Clin Pharmacol Ther; 1987 Jan; 41(1):74-9. PubMed ID: 3802709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antihypertensive mechanism of delapril, a newly developed converting enzyme inhibitor, is related to the suppression of vascular angiotensin II release in the spontaneously hypertensive rat.
    Mizuno K; Tani M; Niimura S; Yamaguchi M; Inagami T; Fukuchi S
    Am J Hypertens; 1991 Jan; 4(1 Pt 2):60S-66S. PubMed ID: 2009151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of a new angiotensin converting enzyme inhibitor: delapril.
    Saruta T; Nishikawa K
    Am J Hypertens; 1991 Jan; 4(1 Pt 2):23S-28S. PubMed ID: 2009144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-hypertensive effect of oral controlled-release microspheres containing an ACE inhibitor (delapril hydrochloride) in rats.
    Akiyama Y; Yoshioka M; Horibe H; Inada Y; Hirai S; Kitamori N; Toguchi H
    J Pharm Pharmacol; 1994 Aug; 46(8):661-5. PubMed ID: 7815280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of the effects of delapril, a new angiotensin converting enzyme inhibitor, on the diurnal variation of arterial pressure in patients with essential hypertension using indirect and direct arterial pressure monitoring methods.
    Miyakawa T; Minamisawa K; Yamada Y; Sasaki O; Fujiki Y; Tochikubo O; Ishii M
    Am J Hypertens; 1991 Jan; 4(1 Pt 2):29S-37S. PubMed ID: 2009145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.
    Kubo SH; Cody RJ
    Clin Pharmacokinet; 1985; 10(5):377-91. PubMed ID: 2994938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial.
    Ruggenenti P; Lauria G; Iliev IP; Fassi A; Ilieva AP; Rota S; Chiurchiu C; Barlovic DP; Sghirlanzoni A; Lombardi R; Penza P; Cavaletti G; Piatti ML; Frigeni B; Filipponi M; Rubis N; Noris G; Motterlini N; Ene-Iordache B; Gaspari F; Perna A; Zaletel J; Bossi A; Dodesini AR; Trevisan R; Remuzzi G;
    Hypertension; 2011 Nov; 58(5):776-83. PubMed ID: 21931073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency.
    Verpooten GA; Genissel PM; Thomas JR; De Broe ME
    Br J Clin Pharmacol; 1991 Aug; 32(2):187-92. PubMed ID: 1657092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans.
    Suzuki H; Kawaratani T; Shioya H; Uji Y; Saruta T
    Biopharm Drug Dispos; 1993 Jan; 14(1):41-50. PubMed ID: 8427943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of temocapril hydrochloride, a novel angiotensin converting enzyme inhibitor, in renal insufficiency.
    Nakashima M; Yamamoto J; Shibata M; Uematsu T; Shinjo H; Akahori T; Shioya H; Sugiyama K; Kawahara Y
    Eur J Clin Pharmacol; 1992; 43(6):657-9. PubMed ID: 1493850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition and safety of omapatrilat in subjects with renal impairment.
    Sica DA; Liao W; Gehr TW; Khan S; Jemal M; Delaney CL; Ferreira IM; Malhotra BK
    Clin Pharmacol Ther; 2000 Sep; 68(3):261-9. PubMed ID: 11014407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.